Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.
10 reports, 3 independent
Updated Sep 16
Gone quiet
- Reports
- 10
- Developments
- 5
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Novartis acquires Sironax's brain delivery platform, which also gained FDA fast track status.1 source
Novartis drug failure increases CEO pressure as the company completes the acquisition of Avidity.1 source
Novartis completes the acquisition of Avidity Biosciences, but the acquired technology platform failed a key clinical trial.1 source
- Novartis made a tender offer to acquire Regulus Therapeutics, filing the necessary documents with the SEC on June 25, 2025.Sub-event
Novartis completes acquisition of Regulus Therapeutics and considers Avidity Biosciences.1 source
Keep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Regulus Therapeutics
Biopharmaceutical company
Nothing else this week.
-
Avidity
American biotech company
Nothing else this week.
Related events
- Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.
- Novartis' trial results are impacting Royalty Pharma's investment decisions.
- Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.
- Novartis conducted REMODEL trials for remibrutinib.
- Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.
Coverage
Newest first; wire copies grouped- biopharmadive.com
- theglobeandmail.com
- biopharmadive.com
- ReutersNovartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Time
- Unknown outlet
- Unknown outlet
- Unknown outlet